Stoke Therapeutics, Inc.

Transaction Overview:

Stoke Therapeutics, Inc. (the “Company”) (Nasdaq:STOK), priced its $97.5 million follow-on offering on November 19, 2020 at a price of $39 per share. The Company issued 2,500,000 shares of common stock. The Company intends to use the net proceeds from this offering to fund research, clinical and process development and manufacturing of its product candidates, including late stage development of STK-001, clinical development of its next target for the treatment of Autosomal Dominant Optic Atrophy, developing additional product candidates, working capital, capital expenditures and other general corporate purposes.

Company Overview:

Stoke Therapeutics (Nasdaq: STOK) is a biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies.